Humacyte (HUMA) Financials

Humacyte logo
$0.50 -0.04 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 +0.01 (+2.79%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Humacyte

Annual Income Statements for Humacyte

This table shows Humacyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-67 -26 -12 -111 -149 -41
Consolidated Net Income / (Loss)
-67 -26 -12 -111 -149 -41
Net Income / (Loss) Continuing Operations
-67 -26 -12 -111 -149 -41
Total Pre-Tax Income
-67 -26 -12 -111 -149 -41
Total Operating Income
-65 -81 -85 -100 -114 -108
Total Gross Profit
1.49 1.26 1.57 0.00 0.00 -7.66
Total Revenue
1.49 1.26 1.57 0.00 0.00 2.04
Operating Revenue
1.49 1.26 1.57 - 0.00 2.04
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 9.70
Operating Cost of Revenue
- - - - 0.00 9.70
Total Operating Expenses
66 82 86 100 114 100
Selling, General & Admin Expense
12 21 23 23 26 31
Research & Development Expense
54 61 63 77 89 69
Total Other Income / (Expense), net
-1.92 55 73 -11 -34 67
Interest Expense
2.20 1.06 6.20 9.02 9.28 34
Interest & Investment Income
0.28 0.02 2.63 5.47 4.10 2.59
Other Income / (Expense), net
0.00 56 76 -7.18 -29 98
Basic Earnings per Share
($11.54) ($0.66) ($0.12) ($1.07) ($1.26) ($0.26)
Weighted Average Basic Shares Outstanding
5.77M 39.97M 103.05M 103.42M 118.48M 158.16M
Diluted Earnings per Share
($11.54) ($0.66) ($0.12) ($1.07) ($1.26) ($0.26)
Weighted Average Diluted Shares Outstanding
5.77M 39.97M 103.05M 103.42M 118.48M 158.16M
Weighted Average Basic & Diluted Shares Outstanding
- 103.00M 103.33M 119.08M 155.12M 222.02M

Quarterly Income Statements for Humacyte

This table shows Humacyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Consolidated Net Income / (Loss)
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Net Income / (Loss) Continuing Operations
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Total Pre-Tax Income
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Total Operating Income
-27 -29 -30 -28 -23 -30 -24 -31 -29 -27 -24
Total Gross Profit
0.00 0.00 0.00 - 0.27 -0.11 0.49 -8.32 -1.54 -0.83 -0.40
Total Revenue
0.00 0.00 0.00 - 0.52 0.30 0.75 0.47 0.50 0.41 1.03
Operating Revenue
0.00 0.00 0.00 - 0.52 0.30 0.75 0.47 0.50 0.41 1.03
Total Cost of Revenue
0.00 0.00 0.00 - 0.25 0.41 0.26 8.78 2.04 1.23 1.43
Operating Cost of Revenue
0.00 0.00 0.00 - 0.25 0.41 0.26 8.78 2.04 1.23 1.43
Total Operating Expenses
27 29 30 28 24 30 25 22 27 26 23
Selling, General & Admin Expense
5.31 5.75 7.31 7.43 8.14 7.81 7.61 7.62 7.93 8.03 9.01
Research & Development Expense
21 24 23 21 15 22 17 15 19 18 14
Total Other Income / (Expense), net
-5.32 -27 -8.97 7.15 62 -7.93 6.88 6.03 11 -9.81 7.98
Interest Expense
1.82 2.52 2.44 2.51 3.00 2.55 2.61 25 2.27 2.32 2.37
Interest & Investment Income
1.03 1.31 0.91 0.85 0.66 0.83 0.59 0.50 0.33 0.39 0.60
Other Income / (Expense), net
-4.53 -26 -7.44 8.80 65 -6.22 8.90 31 13 -7.87 9.75
Basic Earnings per Share
($0.29) ($0.48) ($0.33) ($0.16) $0.28 ($0.24) ($0.11) ($0.19) ($0.09) ($0.16) ($0.06)
Weighted Average Basic Shares Outstanding
108.25M 119.17M 119.41M 118.48M 131.50M 155.44M 158.31M 158.16M 197.85M 234.18M 277.80M
Diluted Earnings per Share
($0.29) ($0.48) ($0.33) ($0.16) $0.28 ($0.24) ($0.11) ($0.19) ($0.09) ($0.16) ($0.06)
Weighted Average Diluted Shares Outstanding
108.25M 119.17M 119.41M 118.48M 131.76M 155.44M 158.31M 158.16M 197.85M 234.18M 277.80M
Weighted Average Basic & Diluted Shares Outstanding
119.08M 119.35M 125.86M 155.12M 155.12M 158.37M 187.27M 222.02M 222.02M 277.80M 277.80M

Annual Cash Flow Statements for Humacyte

This table details how cash moves in and out of Humacyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-54 178 -68 -69 14 -44
Net Cash From Operating Activities
-56 -81 -71 -73 -98 -105
Net Cash From Continuing Operating Activities
-56 -81 -71 -73 -98 -105
Net Income / (Loss) Continuing Operations
-67 -26 -12 -111 -149 -41
Consolidated Net Income / (Loss)
-67 -26 -12 -111 -149 -41
Depreciation Expense
6.29 6.18 6.15 5.66 5.10 5.33
Amortization Expense
2.06 3.04 3.61 2.54 2.09 2.02
Non-Cash Adjustments To Reconcile Net Income
4.89 -7.64 5.77 12 14 50
Changes in Operating Assets and Liabilities, net
-2.29 -56 -75 17 29 -122
Net Cash From Investing Activities
-0.27 -8.22 4.85 -0.17 -1.57 -0.88
Net Cash From Continuing Investing Activities
-0.27 -8.22 4.85 -0.17 -1.57 -0.88
Purchase of Property, Plant & Equipment
-0.32 -0.22 -1.05 -2.28 -1.57 -0.88
Sale and/or Maturity of Investments
- 0.00 16 2.11 0.00 0.00
Net Cash From Financing Activities
2.05 267 -1.45 4.51 114 61
Net Cash From Continuing Financing Activities
2.05 267 -1.45 4.51 114 62
Repayment of Debt
- - 0.00 -33 0.00 -89
Repurchase of Common Equity
- - - 0.00 -0.35 -0.34
Issuance of Debt
3.25 30 0.00 39 20 40
Issuance of Common Equity
0.00 - - 0.00 96 113
Other Financing Activities, net
-1.20 241 -1.45 -1.69 -1.57 -2.69
Cash Interest Paid
0.00 1.12 2.67 1.61 0.00 0.00

Quarterly Cash Flow Statements for Humacyte

This table details how cash moves in and out of Humacyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
35 -22 -23 24 18 -25 -69 31 -1.96 31 -15
Net Cash From Operating Activities
-27 -21 -23 -27 -29 -26 -24 -26 -25 -22 -15
Net Cash From Continuing Operating Activities
-27 -21 -23 -27 -29 -26 -24 -26 -25 -22 -15
Net Income / (Loss) Continuing Operations
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Consolidated Net Income / (Loss)
-32 -57 -39 -21 39 -38 -18 -25 -18 -37 -16
Depreciation Expense
1.27 1.26 1.29 1.29 1.31 1.34 1.34 1.34 1.34 1.34 1.28
Amortization Expense
0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.45 0.73 0.75 0.76
Non-Cash Adjustments To Reconcile Net Income
2.87 3.56 3.61 3.85 4.64 4.55 4.75 36 5.63 3.50 2.58
Changes in Operating Assets and Liabilities, net
-0.11 30 11 -11 -74 4.84 -13 -39 -15 9.16 -4.06
Net Cash From Financing Activities
63 -0.47 0.85 51 47 2.17 -45 57 23 54 -0.41
Net Cash From Continuing Financing Activities
63 -0.47 0.85 51 47 2.07 -44 57 23 54 -0.41
Repurchase of Common Equity
- - - - - - 0.10 - - - -0.23
Other Financing Activities, net
-0.60 -0.36 -0.16 0.05 -0.63 -0.73 -0.74 -0.59 0.00 -0.14 -0.18

Annual Balance Sheets for Humacyte

This table presents Humacyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
107 287 204 128 138 116
Total Current Assets
41 229 154 83 48 68
Cash & Equivalents
40 218 150 80 45 50
Accounts Receivable
0.11 0.18 0.03 - 0.00 0.44
Inventories, net
- - - - 0.00 14
Prepaid Expenses
1.41 3.66 2.30 2.83 2.92 3.27
Other Current Assets
- - - - - 0.00
Plant, Property, & Equipment, net
41 35 30 27 23 19
Total Noncurrent Assets
24 22 20 18 67 30
Noncurrent Note & Lease Receivables
23 21 19 17 15 29
Other Noncurrent Operating Assets
0.77 0.73 0.68 0.84 51 0.88
Total Liabilities & Shareholders' Equity
107 287 204 128 138 116
Total Liabilities
36 164 87 115 191 113
Total Current Liabilities
11 11 20 18 20 18
Accounts Payable
2.27 2.09 1.60 6.49 4.49 5.40
Accrued Expenses
4.59 6.76 7.11 9.34 11 11
Other Current Liabilities
1.77 2.03 2.31 2.61 3.16 2.43
Total Noncurrent Liabilities
25 153 68 96 171 95
Long-Term Debt
0.82 27 20 39 0.00 35
Capital Lease Obligations
23 21 19 16 14 27
Other Noncurrent Operating Liabilities
0.73 105 29 41 157 32
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-350 122 117 14 -53 3.11
Total Preferred & Common Equity
-350 122 117 14 -53 3.11
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-350 122 117 14 -53 3.11
Common Stock
38 537 543 551 633 730
Retained Earnings
-388 -415 -427 -537 -686 -727

Quarterly Balance Sheets for Humacyte

This table presents Humacyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
149 161 138 115 163 139 92 111 138 126
Total Current Assets
103 118 96 23 74 52 41 64 93 83
Cash & Equivalents
100 116 94 21 63 38 19 49 80 65
Accounts Receivable
0.00 - - - 0.49 0.39 1.08 0.43 0.33 0.81
Inventories, net
- - - - 8.02 11 18 9.92 6.99 5.61
Prepaid Expenses
2.87 2.42 2.55 2.43 2.35 2.24 2.37 4.70 5.57 2.62
Other Current Assets
- - - - - - - - - 9.12
Plant, Property, & Equipment, net
28 26 25 24 22 21 20 17 16 15
Total Noncurrent Assets
19 18 17 68 66 66 30 30 29 28
Noncurrent Note & Lease Receivables
18 17 17 16 15 14 29 29 28 28
Other Noncurrent Operating Assets
0.86 0.83 0.82 51 51 51 0.88 0.88 0.88 0.21
Total Liabilities & Shareholders' Equity
149 161 138 115 163 139 92 111 138 126
Total Liabilities
112 135 167 178 127 135 96 99 107 108
Total Current Liabilities
15 14 18 21 20 21 26 16 15 25
Accounts Payable
3.02 3.45 6.01 6.90 5.57 6.63 9.58 5.08 4.16 2.82
Accrued Expenses
9.59 7.92 8.95 11 9.70 9.19 10 8.68 9.27 12
Other Current Liabilities
2.53 2.72 2.80 2.89 3.07 3.15 2.67 2.43 1.52 10
Total Noncurrent Liabilities
97 121 149 158 106 114 71 83 92 83
Long-Term Debt
37 58 60 62 65 66 18 36 36 37
Capital Lease Obligations
17 16 15 14 13 12 27 28 28 29
Other Noncurrent Operating Liabilities
43 47 74 81 29 35 26 19 27 17
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
37 26 -28 -64 36 4.05 -4.75 12 31 18
Total Preferred & Common Equity
37 26 -28 -64 36 4.05 -4.75 12 31 18
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
37 26 -28 -64 36 4.05 -4.75 12 31 18
Common Stock
549 595 598 601 683 689 697 756 813 815
Retained Earnings
-512 -569 -626 -665 -647 -685 -702 -744 -781 -797

Annual Metrics And Ratios for Humacyte

This table displays calculated financial ratios and metrics derived from Humacyte's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
12,855,000.00 103,003,384.00 103,118,461.00 103,575,256.00 - 187,271,321.00
DEI Adjusted Shares Outstanding
12,855,000.00 103,003,384.00 103,118,461.00 103,575,256.00 - 187,271,321.00
DEI Earnings Per Adjusted Shares Outstanding
-5.18 -0.26 -0.12 -1.07 - -0.22
Growth Metrics
- - - - - -
Revenue Growth
0.00% -15.29% 23.91% -100.00% 0.00% 0.00%
EBITDA Growth
0.00% 71.18% 108.40% -7,370.34% -37.68% 98.12%
EBIT Growth
0.00% 60.64% 66.99% -1,177.38% -33.86% 93.10%
NOPAT Growth
0.00% -25.71% -4.15% -18.29% -14.34% 5.47%
Net Income Growth
0.00% 60.20% 54.81% -825.83% -34.24% 72.54%
EPS Growth
0.00% 94.28% 81.82% -791.67% -17.76% 79.37%
Operating Cash Flow Growth
0.00% -46.11% 12.39% -3.06% -33.85% -7.05%
Free Cash Flow Firm Growth
0.00% 0.00% -330.18% 64.36% -58.04% -1,834.29%
Invested Capital Growth
0.00% -196.06% 123.35% -193.75% -71.80% 118.09%
Revenue Q/Q Growth
0.00% 0.00% -10.16% 0.00% 0.00% 29.73%
EBITDA Q/Q Growth
0.00% 0.00% -97.19% -28.36% 3.68% 88.31%
EBIT Q/Q Growth
0.00% 0.00% -121.64% -24.73% 3.52% 66.13%
NOPAT Q/Q Growth
0.00% 0.00% 30.69% -5.70% -1.69% -2.61%
Net Income Q/Q Growth
0.00% 0.00% -134.84% -23.92% 2.73% -10.45%
EPS Q/Q Growth
0.00% 0.00% -101.90% -24.42% 5.97% -13.04%
Operating Cash Flow Q/Q Growth
0.00% -8.34% 3.38% -0.13% -8.30% 0.43%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 27.72% 10.34% -65.19%
Invested Capital Q/Q Growth
0.00% 0.00% 353.89% -37.29% -164.65% -36.48%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 100.00% 0.00% 0.00% -376.06%
EBITDA Margin
-3,772.57% -1,283.53% 87.03% 0.00% 0.00% -125.52%
Operating Margin
-4,332.66% -6,429.77% -5,404.35% 0.00% 0.00% -5,306.04%
EBIT Margin
-4,332.66% -2,013.38% -536.36% 0.00% 0.00% -485.92%
Profit (Net Income) Margin
-4,461.70% -2,096.36% -764.54% 0.00% 0.00% -2,003.58%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
102.98% 104.12% 142.54% 103.31% 103.60% 412.33%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-79.19% -5,057.44% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
77.85% -5,089.30% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
-14.94% 5,029.98% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-94.13% -27.46% -10.01% -169.81% 760.17% 164.78%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -990.49% 0.00% 0.00% -1,156.53%
Operating Return on Assets (OROA)
-60.55% -12.93% -3.42% 0.00% 0.00% -7.79%
Return on Assets (ROA)
-62.35% -13.47% -4.88% 0.00% 0.00% -32.12%
Return on Common Equity (ROCE)
466.60% 32.49% -10.01% -169.81% 760.17% 164.78%
Return on Equity Simple (ROE_SIMPLE)
18.99% -21.67% -10.23% -817.78% 282.33% 0.00%
Net Operating Profit after Tax (NOPAT)
-45 -57 -59 -70 -80 -76
NOPAT Margin
-3,032.86% -4,500.84% -3,783.04% 0.00% 0.00% -3,714.22%
Net Nonoperating Expense Percent (NNEP)
-157.04% 31.87% 33.60% -62.84% 2,117.32% 376.67%
Return On Investment Capital (ROIC_SIMPLE)
- - - -102.33% -329.47% -115.52%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 476.06%
SG&A Expenses to Revenue
805.70% 1,673.00% 1,462.17% 0.00% 0.00% 1,529.49%
R&D to Revenue
3,626.96% 4,856.77% 4,042.17% 0.00% 0.00% 3,400.49%
Operating Expenses to Revenue
4,432.66% 6,529.77% 5,504.35% 0.00% 0.00% 4,929.98%
Earnings before Interest and Taxes (EBIT)
-65 -25 -8.39 -107 -144 -9.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-56 -16 1.36 -99 -136 -2.56
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 6.11 1.86 21.72 0.00 57.86
Price to Tangible Book Value (P/TBV)
0.00 6.11 1.86 21.72 0.00 57.86
Price to Revenue (P/Rev)
87.68 591.27 139.03 0.00 0.00 88.26
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
9.42 0.00 8.86 0.00 0.00 12.76
Enterprise Value to Revenue (EV/Rev)
360.94 451.10 72.50 0.00 0.00 94.11
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 83.30 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 10.34 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.37 0.40 0.41 4.05 -1.46 20.08
Long-Term Debt to Equity
0.34 0.40 0.34 4.05 -1.46 20.08
Financial Leverage
-0.19 -0.99 -1.18 -0.99 -0.17 0.37
Leverage Ratio
1.51 2.04 2.05 2.55 -6.80 -5.13
Compound Leverage Factor
1.55 2.12 2.93 2.63 -7.05 -21.15
Debt to Total Capital
27.17% 28.40% 29.00% 80.21% 316.70% 95.26%
Short-Term Debt to Total Capital
2.53% 0.00% 5.20% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
24.64% 28.40% 23.80% 80.21% 316.70% 95.26%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
433.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-361.02% 71.60% 71.00% 19.79% -216.70% 4.74%
Debt to EBITDA
-0.47 -2.99 35.07 -0.55 -0.56 -24.40
Net Debt to EBITDA
0.24 10.92 -76.45 0.26 -0.24 -4.66
Long-Term Debt to EBITDA
-0.43 -2.99 28.77 -0.55 -0.56 -24.40
Debt to NOPAT
-0.58 -0.85 -0.81 -0.78 -0.96 -0.82
Net Debt to NOPAT
0.30 3.11 1.76 0.36 -0.40 -0.16
Long-Term Debt to NOPAT
-0.53 -0.85 -0.66 -0.78 -0.96 -0.82
Altman Z-Score
-4.56 1.33 -0.77 -6.48 -8.16 -7.55
Noncontrolling Interest Sharing Ratio
595.69% 218.30% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
3.69 20.75 7.88 4.52 2.40 3.69
Quick Ratio
3.56 20.42 7.76 4.36 2.25 2.77
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 55 -127 -45 -71 -174
Operating Cash Flow to CapEx
-20,734.33% -36,904.55% -6,787.12% -3,215.13% -6,241.86% -11,882.58%
Free Cash Flow to Firm to Interest Expense
0.00 51.80 -20.46 -5.01 -7.70 -5.19
Operating Cash Flow to Interest Expense
-25.24 -76.31 -11.47 -8.13 -10.58 -3.13
Operating Cash Flow Less CapEx to Interest Expense
-25.36 -76.51 -11.64 -8.38 -10.75 -3.16
Efficiency Ratios
- - - - - -
Asset Turnover
0.01 0.01 0.01 0.00 0.00 0.02
Accounts Receivable Turnover
13.19 8.74 15.12 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.04 0.03 0.05 0.00 0.00 0.10
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 1.96
Days Sales Outstanding (DSO)
27.66 41.76 24.14 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 186.11
Cash Conversion Cycle (CCC)
27.66 41.76 24.14 0.00 0.00 -186.11
Capital & Investment Metrics
- - - - - -
Invested Capital
57 -55 13 -12 -21 15
Invested Capital Turnover
0.03 1.12 -0.07 0.00 0.00 -0.06
Increase / (Decrease) in Invested Capital
0.00 -112 68 -25 -8.62 98
Enterprise Value (EV)
538 570 113 269 668 192
Market Capitalization
131 747 218 294 636 180
Book Value per Share
($27.25) $1.19 $1.13 $0.13 ($0.42) $0.02
Tangible Book Value per Share
($27.25) $1.19 $1.13 $0.13 ($0.42) $0.02
Total Capital
97 171 165 68 24 66
Total Debt
26 48 48 55 77 62
Total Long-Term Debt
24 48 39 55 77 62
Net Debt
-14 -177 -104 -26 32 12
Capital Expenditures (CapEx)
0.27 0.22 1.05 2.28 1.57 0.88
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-7.26 -7.21 -8.68 -16 -17 -1.07
Debt-free Net Working Capital (DFNWC)
33 218 143 65 28 49
Net Working Capital (NWC)
30 218 135 65 28 49
Net Nonoperating Expense (NNE)
21 -30 -47 41 69 -35
Net Nonoperating Obligations (NNO)
-14 -177 -104 -26 32 12
Total Depreciation and Amortization (D&A)
8.35 9.22 9.76 8.20 7.19 7.35
Debt-free, Cash-free Net Working Capital to Revenue
-487.06% -571.02% -554.63% 0.00% 0.00% -52.70%
Debt-free Net Working Capital to Revenue
2,190.95% 17,283.45% 9,150.10% 0.00% 0.00% 2,425.07%
Net Working Capital to Revenue
2,026.56% 17,283.45% 8,602.43% 0.00% 0.00% 2,425.07%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.66) ($0.12) ($1.07) ($1.26) ($0.26)
Adjusted Weighted Average Basic Shares Outstanding
0.00 39.97M 103.05M 103.42M 118.48M 158.16M
Adjusted Diluted Earnings per Share
$0.00 ($0.66) ($0.12) ($1.07) ($1.26) ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 39.97M 103.05M 103.42M 118.48M 158.16M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 103.00M 103.33M 119.08M 155.12M 222.02M
Normalized Net Operating Profit after Tax (NOPAT)
-45 -57 -59 -70 -80 -76
Normalized NOPAT Margin
-3,032.86% -4,500.84% -3,783.04% 0.00% 0.00% -3,714.22%
Pre Tax Income Margin
-4,461.70% -2,096.36% -764.54% 0.00% 0.00% -2,003.58%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-29.34 -23.90 -1.35 -11.89 -15.47 -0.30
NOPAT to Interest Expense
-20.54 -53.43 -9.55 -7.76 -8.63 -2.26
EBIT Less CapEx to Interest Expense
-29.46 -24.11 -1.52 -12.14 -15.64 -0.32
NOPAT Less CapEx to Interest Expense
-20.66 -53.63 -9.72 -8.02 -8.80 -2.28
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% -14.90% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -14.90% 0.00% 0.00% -0.24% -0.83%

Quarterly Metrics And Ratios for Humacyte

This table displays calculated financial ratios and metrics derived from Humacyte's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
119,083,728.00 119,084,353.00 119,351,122.00 - 155,118,816.00 155,118,816.00 158,372,173.00 187,271,321.00 222,019,108.00 222,019,108.00 277,798,105.00
DEI Adjusted Shares Outstanding
119,083,728.00 119,084,353.00 119,351,122.00 - 155,118,816.00 155,118,816.00 158,372,173.00 187,271,321.00 222,019,108.00 222,019,108.00 277,798,105.00
DEI Earnings Per Adjusted Shares Outstanding
-0.27 -0.48 -0.33 - 0.25 -0.24 -0.11 -0.13 -0.08 -0.17 -0.06
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.26% 34.88% 36.52%
EBITDA Growth
14.55% -199.06% -48.99% 22.98% 247.71% 36.50% 62.01% 110.53% -131.42% 3.81% 13.90%
EBIT Growth
15.33% -176.54% -45.46% 21.36% 233.32% 35.19% 58.89% 100.27% -137.80% 2.99% 11.10%
NOPAT Growth
-18.06% -10.36% -22.79% -7.28% -24.61% -0.77% 19.33% -9.78% 12.64% 9.19% 3.57%
Net Income Growth
13.72% -149.55% -50.81% 16.59% 222.71% 33.54% 55.33% -18.45% -145.02% 2.27% 11.26%
EPS Growth
19.44% -118.18% -32.00% 33.33% 196.55% 50.00% 66.67% -18.75% -132.14% 33.33% 45.45%
Operating Cash Flow Growth
-46.70% 5.80% -76.11% -39.48% -4.59% -24.06% -4.35% 1.70% 12.23% 16.48% 37.36%
Free Cash Flow Firm Growth
93.08% 248.91% -63.40% -270.07% -1,834.16% -532.42% -119.46% -332.77% 106.13% 110.24% 74.83%
Invested Capital Growth
-841.49% -12,539.73% 10.87% -71.80% 437.12% 199.88% 403.51% 118.09% -49.32% -65.62% -17.95%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -41.78% 150.17% -37.98% 6.00% -17.98% 153.20%
EBITDA Q/Q Growth
-29.22% -83.08% 33.19% 51.27% 347.82% -178.70% 60.03% 113.51% -839.05% -140.96% 64.22%
EBIT Q/Q Growth
-26.86% -78.26% 32.07% 48.81% 315.09% -186.66% 56.91% 100.34% -29,681.13% -122.41% 60.51%
NOPAT Q/Q Growth
-1.51% -10.99% -2.49% 7.09% -17.92% 10.24% 17.95% -26.43% 6.16% 6.70% 12.88%
Net Income Q/Q Growth
-27.05% -77.65% 30.82% 46.58% 286.91% -196.22% 53.50% -41.66% 28.97% -108.88% 57.78%
EPS Q/Q Growth
-20.83% -65.52% 31.25% 51.52% 275.00% -185.71% 54.17% -72.73% 52.63% -77.78% 62.50%
Operating Cash Flow Q/Q Growth
-43.52% 22.15% -7.59% -16.02% -7.62% 7.65% 9.50% -9.29% 3.90% 12.12% 32.12%
Free Cash Flow Firm Q/Q Growth
-172.59% 659.78% -183.85% 50.08% -277.19% -25.15% 57.45% -146.68% 104.67% 108.85% -204.64%
Invested Capital Q/Q Growth
-29.44% -200.11% 83.29% -164.65% 163.06% -11.09% -49.21% -36.48% 76.70% -39.68% 21.19%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 52.22% -37.21% 65.47% -1,780.51% -311.72% -203.20% -39.01%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 8,376.98% -11,323.92% -1,809.16% 394.22% -2,748.69% -8,075.12% -1,140.95%
Operating Margin
0.00% 0.00% 0.00% 0.00% -4,484.33% -9,876.08% -3,239.04% -6,603.00% -5,845.45% -6,649.26% -2,287.84%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 8,022.63% -11,941.86% -2,056.84% 11.35% -3,167.27% -8,588.42% -1,339.40%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 7,570.41% -12,510.96% -2,325.37% -5,311.35% -3,559.39% -9,064.53% -1,511.48%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
102.52% 102.17% 104.05% 108.59% 94.36% 104.77% 113.06% -46,800.00% 112.38% 105.54% 112.85%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -125.80% 0.00% -449.01% 0.00% -208.94% -315.35% -178.16%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -617.75% 0.00% -450.04% 0.00% -192.10% -446.53% -171.94%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 251.66% 0.00% 554.33% 0.00% -126.11% -345.18% -384.40%
Return on Equity (ROE)
-195.68% -850.81% 1,143.87% 760.17% 125.86% 484.10% 105.32% 164.78% -335.06% -660.53% -562.55%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -277.95% -367.24% -444.72% -1,156.53% -136.47% -150.90% -338.71%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 25.60% -70.51% -31.33% 0.18% -46.76% -131.58% -29.57%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 24.16% -73.87% -35.42% -85.15% -52.55% -138.87% -33.37%
Return on Common Equity (ROCE)
-195.68% -850.81% 1,143.87% 760.17% 125.86% 484.10% 105.32% 164.78% -335.06% -660.53% -562.55%
Return on Equity Simple (ROE_SIMPLE)
-404.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-19 -21 -21 -20 -23 -21 -17 -22 -20 -19 -16
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -4,484.33% -6,913.26% -2,267.33% -4,622.10% -4,091.82% -4,654.48% -1,601.49%
Net Nonoperating Expense Percent (NNEP)
-21.23% -91.05% 354.22% 39.44% 491.95% 139.38% 1.04% -34.78% -16.84% 131.18% -6.22%
Return On Investment Capital (ROIC_SIMPLE)
-18.61% -44.02% -165.66% -80.90% -20.12% -24.59% -39.57% -32.94% -26.97% -19.70% -19.61%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 47.78% 137.21% 34.53% 1,880.51% 411.72% 303.20% 139.01%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 1,573.69% 2,594.35% 1,010.62% 1,630.84% 1,602.02% 1,977.09% 876.85%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 2,982.21% 7,310.96% 2,293.89% 3,127.41% 3,931.72% 4,468.97% 1,371.98%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 4,555.90% 9,905.32% 3,304.52% 4,758.24% 5,533.74% 6,446.06% 2,248.83%
Earnings before Interest and Taxes (EBIT)
-31 -55 -38 -19 41 -36 -15 0.05 -16 -35 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -54 -36 -17 43 -34 -14 1.84 -14 -33 -12
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
14.16 0.00 0.00 0.00 7.34 80.01 0.00 57.86 11.59 5.54 7.96
Price to Tangible Book Value (P/TBV)
14.16 0.00 0.00 0.00 7.34 80.01 0.00 57.86 11.59 5.54 7.96
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 511.56 396.33 175.41 88.26 66.82 81.69 60.02
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 5.36 7.87 12.85 12.76 5.63 9.86 7.48
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 543.20 448.33 193.50 94.11 74.22 74.50 60.59
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.82 -2.66 -1.20 -1.46 2.20 19.88 -10.08 20.08 5.46 2.07 3.65
Long-Term Debt to Equity
2.82 -2.66 -1.20 -1.46 2.15 19.36 -9.44 20.08 5.46 2.07 3.65
Financial Leverage
-1.16 -2.41 -0.38 -0.17 -0.41 -1.00 -1.23 0.37 0.66 0.77 2.24
Leverage Ratio
3.19 9.33 -9.88 -6.80 5.21 -11.43 -3.01 -5.13 5.73 7.84 16.31
Compound Leverage Factor
3.27 9.54 -10.28 -7.39 4.92 -11.98 -3.41 2,400.79 6.44 8.28 18.40
Debt to Total Capital
73.84% 160.30% 598.79% 316.70% 68.73% 95.21% 111.01% 95.26% 84.52% 67.41% 78.48%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 1.47% 2.50% 7.12% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
73.84% 160.30% 598.79% 316.70% 67.26% 92.71% 103.89% 95.26% 84.52% 67.41% 78.48%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
26.16% -60.30% -498.79% -216.70% 31.27% 4.79% -11.01% 4.74% 15.48% 32.59% 21.52%
Debt to EBITDA
-0.79 -0.58 -0.54 -0.56 -1.24 -1.83 -2.19 -24.40 -1.07 -1.11 -1.17
Net Debt to EBITDA
0.44 0.14 -0.40 -0.24 -0.26 -0.96 -1.30 -4.66 -0.25 0.26 -0.02
Long-Term Debt to EBITDA
-0.79 -0.58 -0.54 -0.56 -1.22 -1.78 -2.05 -24.40 -1.07 -1.11 -1.17
Debt to NOPAT
-1.01 -1.01 -0.97 -0.96 -1.02 -1.03 -0.65 -0.82 -0.80 -0.83 -0.85
Net Debt to NOPAT
0.57 0.25 -0.71 -0.40 -0.21 -0.55 -0.39 -0.16 -0.19 0.20 -0.02
Long-Term Debt to NOPAT
-1.01 -1.01 -0.97 -0.96 -1.00 -1.01 -0.61 -0.82 -0.80 -0.83 -0.85
Altman Z-Score
-3.16 -4.92 -6.99 -5.18 -3.08 -6.04 -9.36 -7.26 -8.55 -7.09 -7.87
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
8.37 5.41 1.10 2.40 3.68 2.45 1.62 3.69 3.93 6.21 3.34
Quick Ratio
8.20 5.27 0.98 2.25 3.16 1.82 0.80 2.77 3.03 5.37 2.64
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-4.71 26 -22 -11 -91 -114 -49 -120 5.59 12 -12
Operating Cash Flow to CapEx
-6,994.12% -11,571.20% -2,452.57% -42,185.71% -12,544.30% -4,650.18% -48,783.67% -66,984.62% -14,345.14% -21,212.50% 0.00%
Free Cash Flow to Firm to Interest Expense
-2.59 10.49 -9.07 -4.40 -30.38 -44.81 -18.58 -4.72 2.46 5.03 -5.15
Operating Cash Flow to Interest Expense
-15.06 -8.47 -9.40 -10.60 -9.53 -10.38 -9.15 -1.03 -11.05 -9.51 -6.32
Operating Cash Flow Less CapEx to Interest Expense
-15.27 -8.54 -9.78 -10.62 -9.61 -10.60 -9.17 -1.03 -11.13 -9.55 -6.32
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.02 0.01 0.02 0.02
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.37 5.86 2.54
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.28 1.36 1.12
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.02 0.04 0.07 0.10 0.10 0.11 0.14
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.05 0.10 0.11 1.96 2.16 2.28 2.18
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 83.46 62.30 143.88
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 284.87 267.61 325.32
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 6,667.53 3,493.49 3,268.73 186.11 169.18 159.89 167.81
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 -6,667.53 -3,493.49 -3,268.73 -186.11 199.16 170.01 301.39
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-16 -47 -7.80 -21 52 47 24 15 27 16 19
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.03 -28.21 0.20 -0.06 0.05 0.07 0.11
Increase / (Decrease) in Invested Capital
-14 -47 0.95 -8.62 68 93 31 98 -26 -31 -4.25
Enterprise Value (EV)
329 553 705 668 281 367 304 192 150 158 145
Market Capitalization
370 572 649 636 264 324 276 180 135 173 144
Book Value per Share
$0.22 ($0.24) ($0.53) ($0.42) $0.29 $0.03 ($0.03) $0.02 $0.05 $0.14 $0.07
Tangible Book Value per Share
$0.22 ($0.24) ($0.53) ($0.42) $0.29 $0.03 ($0.03) $0.02 $0.05 $0.14 $0.07
Total Capital
100 47 13 24 115 85 43 66 75 96 84
Total Debt
74 75 76 77 79 81 48 62 63 65 66
Total Long-Term Debt
74 75 76 77 78 78 45 62 63 65 66
Net Debt
-42 -18 56 32 16 43 28 12 15 -15 1.35
Capital Expenditures (CapEx)
0.39 0.18 0.93 0.06 0.23 0.57 0.05 0.04 0.18 0.10 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -15 -19 -17 -7.48 -5.27 -0.65 -1.07 -1.13 -2.06 -6.61
Debt-free Net Working Capital (DFNWC)
104 78 2.06 28 55 33 19 49 47 78 58
Net Working Capital (NWC)
104 78 2.06 28 54 31 16 49 47 78 58
Net Nonoperating Expense (NNE)
13 36 18 1.28 -62 17 0.44 3.22 -2.64 18 -0.93
Net Nonoperating Obligations (NNO)
-42 -18 56 32 16 43 28 12 15 -15 1.35
Total Depreciation and Amortization (D&A)
1.79 1.78 1.81 1.81 1.83 1.86 1.87 1.79 2.07 2.08 2.04
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -1,447.00% -644.38% -41.12% -52.70% -56.00% -97.31% -275.67%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 10,709.09% 4,005.01% 1,199.36% 2,425.07% 2,351.69% 3,669.92% 2,417.28%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 10,382.21% 3,746.33% 1,003.82% 2,425.07% 2,351.69% 3,669.92% 2,417.28%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.29) ($0.48) ($0.33) ($0.16) $0.28 ($0.24) ($0.11) ($0.19) ($0.09) ($0.16) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding
108.25M 119.17M 119.41M 118.48M 131.50M 155.44M 158.31M 158.16M 197.85M 234.18M 277.80M
Adjusted Diluted Earnings per Share
($0.29) ($0.48) ($0.33) ($0.16) $0.28 ($0.24) ($0.11) ($0.19) ($0.09) ($0.16) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding
108.25M 119.17M 119.41M 118.48M 131.76M 155.44M 158.31M 158.16M 197.85M 234.18M 277.80M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
119.08M 119.35M 125.86M 155.12M 155.12M 158.37M 187.27M 222.02M 222.02M 277.80M 277.80M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -21 -21 -20 -16 -21 -17 -22 -20 -19 -16
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -3,139.03% -6,913.26% -2,267.33% -4,622.10% -4,091.82% -4,654.48% -1,601.49%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 7,570.41% -12,510.96% -2,325.37% -5,311.35% -3,559.39% -9,064.53% -1,511.48%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-17.13 -22.05 -15.45 -7.69 13.83 -14.12 -5.93 0.00 -6.90 -15.02 -5.81
NOPAT to Interest Expense
-10.24 -8.21 -8.68 -7.84 -7.73 -8.18 -6.54 -0.85 -8.92 -8.14 -6.95
EBIT Less CapEx to Interest Expense
-17.35 -22.12 -15.84 -7.71 13.75 -14.35 -5.95 0.00 -6.98 -15.07 -5.81
NOPAT Less CapEx to Interest Expense
-10.46 -8.28 -9.06 -7.86 -7.80 -8.40 -6.56 -0.85 -9.00 -8.19 -6.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.25% -0.23% -0.24% 0.00% -0.75% -0.92% -0.83% 0.00% 0.00% -0.24%

Financials Breakdown Chart

Key Financial Trends

Humacyte’s Q2 2026 statements show improving liquidity but continued operating losses. Revenue was $406,000, down from $495,000 in Q1 2026 but up from $301,000 in Q2 2025. The company remains in an early commercial stage, with revenue insufficient to cover production, research and development, and corporate expenses.

  • Cash position improved materially. Cash and equivalents increased to $79.9 million at June 30, 2026, from $48.5 million at the end of Q1 2026 and $38.0 million at the end of Q2 2025. The increase was primarily driven by $53.7 million of common-stock issuance during the quarter.
  • Short-term liquidity is strong. Current assets of $92.8 million were more than six times current liabilities of $14.9 million. Humacyte also reported no short-term debt, providing flexibility to fund near-term operations.
  • Operating cash burn improved sequentially. Cash used in operating activities declined to $22.1 million in Q2 2026 from $25.1 million in Q1 2026 and $26.4 million in Q2 2025. This suggests some improvement in cash management, although the company is still consuming substantial cash.
  • The balance sheet returned to positive equity. Total equity rose to $31.3 million from $11.6 million in Q1 2026. Humacyte had negative equity in Q3 2025 and throughout the provided 2024 balance-sheet data, so the improvement is notable.
  • Inventory declined. Net inventory fell to $7.0 million from $9.9 million in Q1 2026 and $18.4 million in Q3 2025. Lower inventory could reduce the amount of capital tied up in production, though future commercial demand will determine whether this trend is favorable.
  • Revenue remains small and volatile. Quarterly revenue increased from $301,000 in Q2 2025 to $753,000 in Q3 2025, then declined to $467,000 in Q4 2025, $495,000 in Q1 2026, and $406,000 in Q2 2026. The company has not yet established a consistent revenue-growth pattern.
  • Debt and lease obligations remain significant. Long-term debt was $36.3 million and capital lease obligations were $28.3 million at the end of Q2 2026. These obligations are manageable relative to total assets, but they add fixed financial commitments while Humacyte remains unprofitable.
  • Gross losses continue. Q2 2026 revenue of $406,000 was more than offset by $1.2 million of cost of revenue, producing a gross loss of $825,000. Gross losses were also reported in Q1 2026 and Q4 2025, indicating that current production economics are not yet profitable.
  • Net losses remain substantial. Humacyte reported a Q2 2026 net loss of $36.8 million, compared with a $17.6 million loss in Q1 2026. The latest loss included $9.8 million of net other expense, in addition to a $27.0 million operating loss.
  • Research spending and dilution are elevated. Research and development expense was $18.1 million in Q2 2026, while total operating expenses reached $26.2 million. Weighted-average basic shares increased to 234.2 million from 197.8 million in Q1 2026 and 155.4 million in Q2 2025, signaling meaningful dilution as the company relies on equity financing.

At the Q2 operating cash-burn rate, the $79.9 million cash balance represents roughly three to four quarters of operating funding before considering additional financing, changes in working capital, or capital requirements. Because recent cash growth has been driven primarily by stock issuance rather than operations, investors should closely monitor revenue growth, gross margins, operating cash flow, and future dilution.

11/17/26 09:34 PM ETAI Generated. May Contain Errors.

Humacyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Humacyte's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Humacyte's net income appears to be on a downward trend, with a most recent value of -$40.83 million in 2025, rising from -$66.52 million in 2020. The previous period was -$148.70 million in 2024. See Humacyte's forecast for analyst expectations on what's next for the company.

Humacyte's total operating income in 2025 was -$108.14 million, based on the following breakdown:
  • Total Gross Profit: -$7.66 million
  • Total Operating Expenses: $100.47 million

Over the last 5 years, Humacyte's total revenue changed from $1.49 million in 2020 to $2.04 million in 2025, a change of 36.7%.

In the past 12 quarters, Humacyte's cash and equivalents has ranged from $19.49 million in Q3 2025 to $115.51 million in Q1 2024, and is currently $64.52 million as of their latest financial filing in Q3 2026.

Humacyte had total debt of $62.42 million at the end of 2025, a 18.9% decrease from 2024, and a 136.8% increase since 2020.

Over the last 5 years, Humacyte's book value per share changed from -27.25 in 2020 to 0.02 in 2025.



Financial statements for NASDAQ:HUMA last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners